Zijing Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zijing Li has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Bingjie Liu
State Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Department of Cardiology, Qilu Hospital of Shandong University, Jinan, Shandong, China (J.Z., L.Y., W.Y., L.C., X. Wang, C.K., Z.L., R.R., W.Q., L.L., W.X., W.S., X. Wu, N.L., B.L., S.W., P.B., Y.Z., C.Z., M.Z.).
1 shared publication- Cheng Zhang
State Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research of MOE, NHC, CAMS and Shandong Province, Department of Cardiology, Qilu Hospital of Shandong University, China
1 shared publication Chengjiang Gao
Key Laboratory of Infection and Immunity of Shandong Province, Department of Immunology, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China (C.G.).
1 shared publicationChunyu Kao
State Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Department of Cardiology, Qilu Hospital of Shandong University, Jinan, Shandong, China (J.Z., L.Y., W.Y., L.C., X. Wang, C.K., Z.L., R.R., W.Q., L.L., W.X., W.S., X. Wu, N.L., B.L., S.W., P.B., Y.Z., C.Z., M.Z.).
1 shared publication- Jie Zhang
State Key Laboratory for Innovation and Transformation of Luobing Theory; Key Laboratory of Cardiovascular Remodeling and Function Research of MOE, NHC, CAMS and Shandong Province; Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China
1 shared publication Lei Cao
State Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Department of Cardiology, Qilu Hospital of Shandong University, Jinan, Shandong, China (J.Z., L.Y., W.Y., L.C., X. Wang, C.K., Z.L., R.R., W.Q., L.L., W.X., W.S., X. Wu, N.L., B.L., S.W., P.B., Y.Z., C.Z., M.Z.).
1 shared publication
Latest Publications
- Top Cited Papers
- 24 February 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (8) , 576-596
Macrophage-Specific E3 Ubiquitin Ligase TRIM31 Reduces Atherosclerotic Plaque Formation by Targeting LOX-1
BACKGROUND: Atherosclerosis is a chronic inflammatory disease marked by lipid accumulation and immune cell infiltration in arterial walls. Macrophages contribute by internalizing oxidized low-density lipoprotein, forming foam cells, and driving inflammation. The ubiquitin–proteasome system regulates immune and inflammatory responses in atherosclerosis. This study investigated the protective role of TRIM31 (tripartite motif-containing 31), an E3 ubiquitin ligase, in macrophage lipid metabolism and inflammation through selective regulation of LOX-1 (lectin-like oxidized low-density lipoprotein receptor-1). METHODS: Transcriptomic profiling, macrophage-specific Trim31 knockout ( Trim31 fl/fl Lyz2 cre ) and overexpression ( Trim31 Lyz2-KI ) mice, and Lox-1 knockout ( Lox-1 −/− ) models were used to examine the impact of TRIM31 in vivo (n=8 per group). TRIM31 substrates were identified using single-cell RNA sequencing of atherosclerotic aortas and proteomic/immunoprecipitation–mass spectrometry analyses. Functional assays were performed in both mouse and human macrophages (n=5–6 per group). Ubiquitination mechanisms were clarified through immunoprecipitation and site-directed mutagenesis. Rescue experiments involved Lox-1 knockdown or reconstitution with wild-type and lysine 12 to arginine variant (K12R) Lox-1 and Trim31 overexpression in Lox-1 −/− or Apoe −/− Lox-1 −/− mice to evaluate the functional importance of Lox-1 ubiquitination in vivo (n=8 per group) and in vitro (n=5 per group). RESULTS: TRIM31 was selectively upregulated in macrophages under oxidized low-density lipoprotein stimulation and in atherosclerosis plaques. Trim31 deficiency exacerbated plaque burden, foam cell formation, and inflammatory signaling (n=8 per group). Single-cell analysis revealed enrichment of lipid transport and inflammatory pathways in Trim31-deficient plaques. LOX-1 was identified as a key TRIM31 substrate. TRIM31 promoted K48-linked ubiquitination of LOX-1 at lysine 12, facilitating its degradation. The atheroprotective effects of Trim31 were abolished in Lox-1 −/− or K12R-variant rescue models. The TRIM31–LOX-1 axis was also confirmed by human macrophages in regulating lipid uptake and inflammation. CONCLUSIONS: TRIM31, an inducible, macrophage-enriched protective factor in atherosclerosis, restricts foam cell formation and inflammation by targeting LOX-1 for proteasomal degradation. These findings position TRIM31 as a promising therapeutic target for macrophage-driven atherogenesis.
- 24 February 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (8) , 576-596
Top Cited PapersMacrophage-Specific E3 Ubiquitin Ligase TRIM31 Reduces Atherosclerotic Plaque Formation by Targeting LOX-1
BACKGROUND: Atherosclerosis is a chronic inflammatory disease marked by lipid accumulation and immune cell infiltration in arterial walls. Macrophages contribute by internalizing oxidized low-density lipoprotein, forming foam cells, and driving inflammation. The ubiquitin–proteasome system regulates immune and inflammatory responses in atherosclerosis. This study investigated the protective role of TRIM31 (tripartite motif-containing 31), an E3 ubiquitin ligase, in macrophage lipid metabolism and inflammation through selective regulation of LOX-1 (lectin-like oxidized low-density lipoprotein receptor-1). METHODS: Transcriptomic profiling, macrophage-specific Trim31 knockout ( Trim31 fl/fl Lyz2 cre ) and overexpression ( Trim31 Lyz2-KI ) mice, and Lox-1 knockout ( Lox-1 −/− ) models were used to examine the impact of TRIM31 in vivo (n=8 per group). TRIM31 substrates were identified using single-cell RNA sequencing of atherosclerotic aortas and proteomic/immunoprecipitation–mass spectrometry analyses. Functional assays were performed in both mouse and human macrophages (n=5–6 per group). Ubiquitination mechanisms were clarified through immunoprecipitation and site-directed mutagenesis. Rescue experiments involved Lox-1 knockdown or reconstitution with wild-type and lysine 12 to arginine variant (K12R) Lox-1 and Trim31 overexpression in Lox-1 −/− or Apoe −/− Lox-1 −/− mice to evaluate the functional importance of Lox-1 ubiquitination in vivo (n=8 per group) and in vitro (n=5 per group). RESULTS: TRIM31 was selectively upregulated in macrophages under oxidized low-density lipoprotein stimulation and in atherosclerosis plaques. Trim31 deficiency exacerbated plaque burden, foam cell formation, and inflammatory signaling (n=8 per group). Single-cell analysis revealed enrichment of lipid transport and inflammatory pathways in Trim31-deficient plaques. LOX-1 was identified as a key TRIM31 substrate. TRIM31 promoted K48-linked ubiquitination of LOX-1 at lysine 12, facilitating its degradation. The atheroprotective effects of Trim31 were abolished in Lox-1 −/− or K12R-variant rescue models. The TRIM31–LOX-1 axis was also confirmed by human macrophages in regulating lipid uptake and inflammation. CONCLUSIONS: TRIM31, an inducible, macrophage-enriched protective factor in atherosclerosis, restricts foam cell formation and inflammation by targeting LOX-1 for proteasomal degradation. These findings position TRIM31 as a promising therapeutic target for macrophage-driven atherogenesis.